# A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)

> **NCT01114854** · PHASE1 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 69 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Topiramate IR
- **DRUG:** Topiramate ER

## Key facts

- **NCT ID:** NCT01114854
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-12
- **Final completion:** 2011-01
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2017-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01114854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01114854, "A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01114854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*